1

Assessment of the Feasibility of Remote Training, At-Home Testing, and Test-Retest

Variability of Clustered Virtual Reality Perimetry

Zer Keen Chia¹, Alan W. Kong¹, Marcus L. Turner¹, Murtaza Saifee¹, Bertil E. Damato¹, Benjamin T. Backus², James J. Blaha², Joel S. Schuman³⁻⁷, Michael Deiner¹, Yvonne Ou¹

Affiliations:

1. Department of Ophthalmology, UCSF School of Medicine, San Francisco, CA, United States 2. Vivid Vision, Inc., San Francisco, CA, United States

3. Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, United States

4. Departments of Biomedical Engineering and Electrical and Computer Engineering, New York University Tandon School of Engineering, Brooklyn, NY, United States

5. Center for Neural Science, NYU, New York, NY, United States

6. Neuroscience Institute, NYU Langone Health, New York, NY, United States

7. Department of Electrical and Computer Engineering, Pratt School of Engineering, Duke University, Durham, NC, United States

Corresponding Author:

Yvonne Ou, MD 10 Koret Way, San Francisco, CA, 94143, USA. Phone: 415-476-0779 Fax: 415-476-0336

Financial Support: This work was made possible, in part, by UCSF Resource Allocation Program award (YO and MD), NEI P30 EY002162 - Core Grant for Vision Research, and by an unrestricted grant from Research to Prevent Blindness, New York, NY.

Conflict of Interest: Benjamin T. Backus and James J. Blaha have employment, equity, and IP in Vivid Vision, Inc. The other authors have no other relevant conflicting relationships.

Abbreviations:

SAP: Static Automated Perimetry; HVF: Humphrey Visual Field; VVP: Vivid Vision Perimetry; MD: Mean Deviation; MS: Mean Sensitivity; SD-OCT: Spectral-Domain Optical Coherence Tomography; GCC: Ganglion Cell Complex; SE: Standard Error of the mean

Key Words:

Glaucoma; Visual Field Testing; Virtual Reality; Feasibility; Remote Training

Running Head: Remote Training and Variability of Clustered VR Perimetry

2

1 Abstract

2 **Objective:** To assess the feasibility of remotely training glaucoma patients to take a ten-session

3 clustered virtual reality (VR) visual field test (VVP-10) at home, analyze results for test-retest

4 variability, and assess correspondence with conventional perimetry.

5 **Design:** Cross-sectional study.

6 **Subjects:** 21 subjects with glaucoma were enrolled and included in the feasibility assessment of

7 remote training. 36 eyes were used for test-retest analysis and determination of concordance with

8 Humphrey Visual Field (HVF) testing.

9 Methods: Subjects were provided with a mobile VR headset containing the VVP-10 test

10 software and trained remotely via video conferencing. Subjects were instructed to complete ten

11 sessions over a 14-day period.

12 Main Outcome Measures: Feasibility was determined by the number of subjects who were able

to independently complete VVP-10 over the 14-day period after one remote training session.

14 Intraclass correlation coefficient (ICC) of average fraction seen across ten sessions and standard

15 error (SE) for the mean were primary outcome measures for assessing test-retest variability.

16 Correlation with HVF mean sensitivity (MS) across eyes, was a secondary outcome measure.

17 **Results:** 20 subjects (95%) successfully completed the VVP-10 test series after one training

18 session. ICC of VVP-10 was 0.95 (95% CI [0.92, 0.97]). Mean SE in units of fraction seen was

19 0.012. The Spearman correlations of VVP-10 average fraction seen versus HVF MS were 0.88

20 (95% CI [0.66, 0.99]) for moderate to advanced glaucoma eyes, and decreased to 0.68 (95% CI

[0.29, 0.94]) when all eyes were included.

22 **Conclusions:** Remote training of patients at home is feasible and subsequent remote clustered

visual field testing using VVP-10 by patients on their own without any further interactions with

- 24 caregivers or study staff was possible. At-home VVP-10 results demonstrated low test-retest
- 25 variability. Future studies must be conducted to determine if VVP-10, taken at home as
- 26 convenient for the patient, may be a viable supplement to provide equivalent or complementary
- 27 results to that of standard in-clinic assessment of visual function in glaucoma.

4

28 Introduction

Visual function is routinely evaluated in glaucoma patients with conventional static 29 automated perimetry (SAP), for example with Humphrey Visual Field (HVF) testing. However, 30 patients dislike taking the test and report feeling pressured to do well.¹ Additional challenges 31 32 include variable testing environments, long clinic wait times, and the need to schedule appointments and travel to clinic.¹ Furthermore, visual field tests have high inherent variability 33 34 due to their short duration which limits the amount of data collected. Variability is also influenced by factors including the testing environment and technician instructions.^{2,3} and the 35 36 need for patients to maintain prolonged fixation throughout the test can cause fixation losses, fatigue, and discomfort.^{1,4} Current tests also require significant clinic infrastructure and resources. 37 38 Studies have demonstrated that time to detection of progression using standard visual 39 field testing regimens can range from 2 to 7 years or more depending on frequency of testing and rate of progression of disease,⁵ with factors such as ethnicity and socioeconomic status affecting 40 the frequency of visual field testing,⁶ time to detection of progression,^{7,8} and severity of disease 41 at first presentation.⁹ Chauhan et al. and the European Glaucoma Society therefore recommend 42 performing six visual field examinations within the first 2 years of diagnosis to identify rapid 43 progressors and establish patients' baseline data,^{10,11} but a study by Fung et al. revealed that most 44 45 patients with newly-diagnosed glaucoma received less than 3 visual fields in the first 2 years following diagnosis.¹² Furthermore, while the American Academy of Ophthalmology 46 recommends at least yearly visual field evaluations in patients with primary open-angle 47 glaucoma,¹³ Stagg et al. found that more than 75% of patients with open-angle glaucoma across 48 49 the United States receive less than one visual field test per year and thus do not meet guidelineadherent monitoring.¹⁴ Given the challenge of obtaining consistent visual field tests, especially 50

5

during the COVID-19 pandemic, there is an unmet need for accessible, patient-friendly visual field testing that would not only enhance the patient experience but also provide physicians with additional data to help deliver the best care possible. One logical alternative to in-clinic visual field testing is at-home testing which patients are amenable to because it enables closer monitoring of their visual function through clustered testing and allows them to undergo testing at their convenience.^{15,16}

57 Vivid Vision Perimetry (VVP, Vivid Vision Inc., San Francisco, CA) has designed a variety of portable and mobile virtual reality-based visual field tests that are configured to run on 58 off-the-shelf head mounted displays using the principle of multi-fixation, ^{17,18} multiple-choice 59 60 perimetry. The patient's task during VVP was designed to reduce fatigue as compared to the 61 button-press task in conventional in-clinic perimetry, with the aim of collecting more data and 62 thus more precise measurements of sensitivity in patients with moderate to severe loss. Briefly, 63 with VVP testing, patients are not required to fixate on a stationary central target for the duration 64 of the test but are instead allowed to move their eyes and head during the test. A fixation task is 65 used to control the retinal positions of the stimuli, although VVP is not a form of eye-movement 66 perimetry and eye position is not monitored. Visual field testing is one of the least popular tests done in clinic,⁴ possibly in part due to the need for patients to suppress their foveation reflex, and 67 68 multi-fixation perimetry may provide a more comfortable testing experience for patients. Indeed, patients report that tests that do not require constant fixation are more comfortable than SAP.^{15,19} 69 70 In this study, we introduce VVP-10, a test with suprathreshold stimuli comprising ten identical sessions that patients complete over a 14-day period at home after remote training. The 71 previously reported suprathreshold screening version of the test, VVP Swift, demonstrated good 72

test-retest reliability, but only two tests per subject were included in the study.¹⁷ The precision of

6

74	patients' visual field measurements is limited both by the number of tests they receive each year
75	and by the number of stimuli presented per test, so we sought to increase precision by increasing
76	the number of sessions per patient and by using a new version of the test that presents stimuli
77	more often at each location.
78	The purpose of this study was to demonstrate the feasibility of remote training of
79	glaucoma patients to complete VVP-10 at home, to assess their at-home test results for test-retest
80	variability using measurements obtained from the series of sessions, and to assess patient
81	discomfort and fatigue. A secondary aim was to determine concordance between the visual field
82	results obtained from VVP-10 and from HVF.
83	Methods
84	Participants for this cross-sectional study were recruited from the patient cohort of the
85	Glaucoma Clinic at the University of California, San Francisco (UCSF), from May 2020 to
86	August 2020. Informed consent was obtained from all participants either in clinic or over Zoom
87	(San Jose, CA). All methods were approved by the UCSF Institutional Review Board, and all
88	research adhered to the tenets of the Declaration of Helsinki and the Health Insurance Portability
89	and Accountability Act.
90	Subject Characteristics
91	Inclusion criteria included subjects aged 18-85 with a diagnosis of primary open-angle
92	glaucoma or secondary forms of glaucoma including steroid-induced, mixed-mechanism, and
93	pseudoexfoliation glaucoma. A diagnosis of glaucoma was made by either optic disc or retinal
94	nerve fiber layer (RNFL) structural abnormalities, reliable and reproducible visual field
95	abnormalities consistent with RNFL damage defined as persistent scotomas on at least 2

96 consecutive HVF tests, or both. Structural abnormalities included neuroretinal rim thinning,

7

97 localized or diffuse RNFL defects, disc hemorrhages, or progressive narrowing of the
98 neuroretinal rim with increased cupping, observed with slit-lamp biomicroscopy and a handheld
99 lens or with spectral-domain OCT imaging (Optovue Inc., Fremont, CA). Subjects who met our
100 inclusion criteria were identified prior to each clinic day, and they were recruited in the order of
101 their visits until our team ran out of Oculus devices; we did not seek to recruit subjects who were
102 younger or otherwise potentially more technologically literate.

Exclusion criteria included best-corrected visual acuity (BCVA) worse than 20/80 or concurrent retinal disease including retinal vein occlusion, wet age-related macular degeneration, or proliferative diabetic retinopathy. Subjects with a history of epilepsy or issues with neck strain or head movement were also excluded from enrollment. Subjects who were unable to complete individual VVP-10 sessions within the allotted maximum time of 30 minutes after training were excluded from test-retest and correlation analyses.

109 VVP-10 Remote Training of Patients in Their Homes

110 Subjects were given a mobile VR headset (Oculus Go, Facebook, Menlo Park, CA) either 111 in-clinic (if they happened to be in clinic) or else shipped via mail. Once at home with the device, each subject was individually trained over Zoom by the investigators (ZKC, MLT) on how to 112 113 take VVP-10. During the training session, the investigators helped each the subject connect the 114 device to WiFi and discussed each step of the test (Figure 1) and the protocol for repeat testing. 115 Patients were instructed on how the test works. Before each stimulus presentation, the test-taker 116 performed a fixation task: they controlled a dot (the "pointer") by moving their head, and the 117 first step of each trial was to connect (partially overlap) this pointer with a fixation point. 0.10 118 seconds after successful connection, the stimulus flashed in the periphery and the subject moved 119 the pointer towards the location of the stimulus, again by moving their head. If the subject did

8

120 not see the stimulus, they could remain still until the next fixation task, resulting in a miss due to 121 a "skipped" stimulus. Moving to the wrong location ($> 30^{\circ}$ away in polar angle) was also counted as a "miss." This cycle of fixation task followed by stimulus task continued until all 122 123 stimuli had been presented at which point the test was complete. After these instructions were 124 given to each subject, they completed a training module within the VR testing environment during which the investigators were available online to troubleshoot. After successful completion 125 126 of the training module and demonstration of an understanding of how to take the test, determined 127 by having subjects explain the steps of the test back to the investigators, subjects were asked to 128 complete 10 identical tests (or sessions) over 14 days. Subjects were allowed to complete up to two sessions per day, but these sessions had to take place at least 30 minutes apart to minimize 129 130 fatigue from prolonged testing. At the end of the 14-day period, the investigators asked subjects 131 to rate the levels of discomfort and fatigue they experienced from the VVP-10 test using a 5-132 point Likert scale (1 = no discomfort or fatigue, 5 = extremely high discomfort or fatigue). 133 Subjects were also asked to rate the levels of discomfort and fatigue they experienced from their 134 prior in-clinic HVF testing.

135 Visual Field Technical Details

The current study used VVP's "24-2-M-FC" test, a fixed-contrast test in which all stimuli had the same suprathreshold contrast. Ten sessions of this 24-2-M-FC test comprised the VVP-10 testing strategy. Preliminary data collected using fixed-contrast stimuli demonstrated an approximately linear relationship between VVP-10 average fraction seen and HVF mean sensitivity in dB, with an average fraction seen of 50% approximately equivalent to a mean sensitivity of 15 dB. The test presented a black-on-white, blurred stimulus that was 0.43° in diameter at half-height, lasting 0.30 seconds. This stimulus was presented at 54 points on a 24-2

143	grid, four times per location, in a random order, and at a canonical blind spot location of (+/-14.0,
144	-1.5 deg) seven times in each eye (total of 2 eyes x 54 locations/eye x 4 stimuli/location = 432
145	stimuli per test, plus 14 blind-spot stimuli). Background luminance was 25 cd/m ² . Fraction seen
146	was the dependent variable; the graded (shallow-slope) nature of the psychometric function
147	causes fraction seen at a given location to vary as a function of stimulus intensity ^{20,21} ; it likewise
148	causes fraction seen for a fixed-intensity stimulus to vary from 0 to 1 depending on sensitivity.
149	Because the stimuli were presented at an optical distance of ~1.4 m (0.7 D), subjects were
150	instructed to continue wearing any distance correction if applicable. All such subjects were able
151	to wear their distance correcting contact lenses or glasses during testing. Progressive lenses were
152	allowed because the test uses pattern-blurred stimuli that make it robust to small amounts of
153	optical blur. ²² When subjects were in clinic, their visual fields were also assessed using
154	conventional SAP testing with the HVF 24-2 SITA-Standard test (Carl Zeiss, Meditec, Inc.
155	Dublin, CA). These tests were not necessarily done on the same day as study enrollment, in
156	which case data from the most recent HVF was obtained via chart review.
157	The fraction seen was measured at each location in each session, and average fraction
158	seen for each eye for each session was computed. Average fraction seen was also computed for
159	each eye across VVP-10 as a whole (across the 10 sessions). Point sensitivity and mean
160	sensitivity (MS) for each eye in dB were the outcome measures for HVF. The cutoffs for
161	reliability indices of HVF were set at a 15% false-positive response rate, a 30% false-negative
162	response rate, and 30% fixation loss rate. VVP-10 does not utilize the same reliability indices
163	and does not incorporate eye-tracking technology to determine fixation losses, but instead uses a
164	fixation task. ^{23,24} It also measures a "blind spot seen (BSS) rate," which is the rate at which
165	stimuli presented at the canonical blind spot, that should be missed, are seen.

10

166 Statistical Analysis

167	Test-retest variability of VVP-10 was determined using the following methods. The
168	intraclass correlation coefficient (ICC) estimate for average fraction seen, across ten VVP
169	sessions, and its 95% confidence interval, were calculated based on a mean rating ($k = 10$),
170	absolute-agreement, two-way mixed effects model. The ICC is one measure of how similar the
171	10 sessions were to one another. The standard error (SE) for the mean across all 10 sessions was
172	calculated. For a given eye, the SE estimated the test-retest variability (SD) in units of the
173	dependent variable, namely fraction seen, for the 10-session VVP-10 test as a whole.
174	Comparison between HVF sensitivity in dB and VVP-10 fraction seen was evaluated by
175	calculating the Spearman correlation coefficient across an eye's tested locations, along with its
176	95% confidence interval using a non-parametric bootstrap that resampled at the individual level
177	with replacement (1,000 iterations). A separate correlation was done across eyes, using MS for
178	HVF and average fraction seen for VVP-10. Comparison of the discomfort and fatigue that
179	subjects experienced during VVP-10 versus HVF were calculated using the Mann-Whitney test.
180	Significance was defined as $P < 0.05$. Data analyses were performed with R version 4.0.4 (R
181	Foundation for Statistical Computing, Vienna, Austria).

182 **Results**

A total of 21 unique subjects and 41 eyes were enrolled in the study. Six subjects received the headset via mail and the rest were given the headset in clinic during a regular care follow-up visit. Fifty-two percent of subjects identified as male, the rest as female, and subjects identified as either Caucasian (62%) or Asian (38%). Of the 21 subjects who were enrolled and trained remotely, one subject was considered to have failed remote training due to their inability to progress past the training module during the training session and consequent inability to

189	complete the VVP-10 sessions. All other subjects (95%) were able to independently complete the
190	individual sessions within the allotted time limit and successfully completed 10 sessions within
191	14 days after one remote training session. Figure 2 shows the grayscale maps from one subject's
192	10 sessions and for the VVP-10 test as a whole, alongside their HVF grayscale maps.
193	Of the 39 eyes from the 20 subjects who completed VVP-10, three eyes were excluded
194	posthoc from analyses as they did not meet inclusion criteria due to the presence of concurrent
195	ocular disease (N = 1) or BCVA worse than $20/80$ (N = 2). A total of 36 eyes from 19 subjects
196	were included in the test-retest analyses. Group characteristics of included eyes are described in
197	Table 1. The mean time elapsed between HVF and VVP-10 testing was 32 days. On average, the
198	response time to "seen" stimuli on VVP-10 was 0.62 seconds compared to 1.00 seconds for
199	"missed" stimuli when the patient responded incorrectly ($P < 0.001$). The average response time
200	for no-response "skipped" stimuli was 2.3 seconds due to the setting of the test's time-out
201	parameter. All eyes except one had VVP-10 blind spot seen rate $< 30\%$.
202	For this set of glaucomatous eyes, the mean average fraction seen was 0.74 ± 0.21 (range
203	0.32 to 0.99). The intraclass correlation coefficient (ICC) of average fraction seen across the ten
204	sessions was 0.95 (95% CI $[0.92 - 0.97]$) and the SE in units of fraction seen was 0.012 on
205	average. The SE for the 10 sessions estimates the SD of their mean or the test-retest variability of
206	VVP-10.
207	For comparison between HVF and VVP-10, one additional eye was excluded due to
208	having an HVF false-positive response rate > 15% for a total of 35 eyes used in concordance
209	analysis. Because the version of VVP-10 in this study employed a suprathreshold stimulus, it
210	could not measure sensitivity at locations with early loss. Indeed, when correlations between
211	HVF point sensitivity and VVP fraction seen in each eye were plotted against HVF MD (Figure

12

218	When comparing one session of HVF to the ten-session VVP-10 test, patients on average
217	<i>P</i> < 0.05, Figure 4B).
216	10 average fraction seen versus HVF MS was, as expected, worse at 0.68 (95% CI [0.29, 0.94]),
215	(95% CI [0.66, 0.99], $P < 0.001$, Figure 4A). Including all 35 eyes, the correlation between VVP-
214	versus HVF MS for the 16 eyes that had HVF MD of -6 dB or worse. The correlation was 0.88
213	better than -6 dB. We therefore examined the correlation between VVP-10 average fraction seen
212	3), there was an inverse relationship between correlation and HVF MD for eyes with MD values

felt that the tests were similarly uncomfortable (average Likert score of 2.0/5 and 1.8/5,

respectively; P = 0.51) and similarly fatiguing (average Likert score of 2.2/5 and 1.7/5,

221 respectively; P = 0.09).

222 Discussion

223 In this study, we demonstrated the feasibility of training subjects remotely in their homes 224 to take a new at-home VR-based visual field test, VVP-10, and the feasibility of their completing 225 its ten sessions over a 14-day period. We estimated the test-retest variability (SD) of the mean 226 VVP-10 test result to be 0.012, and we interpret this value as demonstrating low test-retest 227 variability. In Figure 4A, VVP-10 average fraction seen ranged from 0.3 to 0.8. Thus, our 228 observed test-retest variation of 0.012 was 2.4% of the range of the data. For the same eyes, HVF 229 MS ranged from 8 to 24 dB. If it could be measured with an equivalent precision of 2.4% within 230 this comparable range, its test-retest variability would be only 0.38 dB, which is lower than the 1.0 dB expected for glaucoma patients who are moderately reliable test takers.²⁵ There is also a 231 232 strong correlation between VVP-10 average fraction seen and HVF MS when subjects with mild 233 glaucoma are excluded, which was appropriate because VVP-10 stimuli were suprathreshold.

13

234 SAP is routinely used in clinic to detect and monitor visual field defects, but many 235 patients do not undergo the recommended frequency of testing and many dislike the testing 236 experience. As a result, various groups have developed alternative tests that can be completed by 237 patients at home for improved monitoring of glaucomatous changes, including Eyecatcher and 238 Virtual Field. In studies of those tests, most patients completed tests remotely, noted the 239 advantages of greater accessibility, and reported feeling that they were playing an active role in their healthcare.^{16,26} Patients enrolled in a study using the tablet-based Melbourne Rapid Fields 240 241 test had good compliance to weekly monitoring over a 12 month period, with 32% of enrolled subjects completing the trial.²⁷ To the best of our knowledge, our study is the first to demonstrate 242 243 the feasibility of training subjects using video conferencing so that the entire process of training 244 and data collection can be completed remotely.

245 Only one subject in our study was unable to progress past the training session, suggesting 246 that remote training of select patients is feasible and that most patients may not need to undergo 247 in-clinic training prior to being given a device for home testing. The reason for failure in this one 248 subject remains unclear but likely involves some combination of challenges with the technology 249 and a poor understanding of utilizing multi-fixation perimetry to register responses with head 250 movement; this subject's age at testing was 83 compared to the average age of 62.2 years. 251 Nevertheless, the low test-retest variability of VVP-10 coupled with successful completion of the 252 VVP-10 test series in all other subjects highlights the potential for remote training and 253 administration of a portable visual field test. The overall correlation of 0.88 between VVP-10 254 average fraction seen and HVF MS in subjects with moderate to advanced glaucoma is similar to correlations obtained using other virtual reality-based head-mounted devices^{28–31} as well as 255 tablet-based perimeters.^{32,33} Finally, although VVP-10 contained 10 sessions, subjects on average 256

14

did not rate VVP-10 as more fatiguing or uncomfortable than a single HVF test. The finding that
patients are amenable to taking tests more regularly has previously been described by various
groups,^{15,16,34,35} but we consider it extraordinary, and an indication of our success in devising a
usable test, that 95% of patients successfully completed the training and that all trained patients
completed their 10 sessions without further prompting.

Strengths of this study include the remote training of subjects in their homes by two different investigators, suggesting that successful remote training does not require superior instruction by an exceptional trainer. That subjects required only one training session indicates the practical application and feasibility of remote training. We enrolled subjects who met our inclusion criteria in the order of their clinic visits and did not seek to recruit younger, potentially more technologically literate subjects.

Limitations of this study include a relatively small sample size and that all subjects 268 269 identified as either Caucasian or Asian. Additionally, although we did not intentionally recruit 270 younger subjects, the average age of our study population was 62.2 years, so our subjects may 271 have been more comfortable using video conferencing for training than the average glaucoma 272 patient would be. Future studies examining the utility of remote training should therefore seek to 273 recruit older patients who may not be as familiar with video technology. VVP testing time per 274 eye per session was also roughly double that of HVF testing. One qualitative study found that 275 patients are willing to undergo increased duration of testing if it leads to more accurate information about their vision,³⁵ but it cannot be assumed that all patients would be amenable to 276 277 such prolonged testing. On the other hand, the overall effort and time to take all 10 sessions of 278 VVP-10 at home may be similar to the time required to schedule a clinic appointment, travel to 279 and from the clinic, and wait in the clinic.

280		In summary, we have demonstrated the feasibility of remote training and at-home testing,	
281	and the low test-retest variability, of VVP-10, a suprathreshold virtual reality-based visual field		
282	test.	Results correlated well with in-clinic visual field testing in eyes with moderate to severe	
283	visual field loss from glaucoma. Future work should address the feasibility of remote training in		
284	older and more ethnically diverse subjects and also focus on the development of a testing		
285	strategy for longitudinal visual field monitoring. Should these studies prove VVP-10 effective		
286	for meeting those clinical needs, patients could in the future receive a testing device via mail,		
287	undergo remote training, and complete the VVP-10 test series without the burden of coming to		
288	clin	c. At-risk patients who would otherwise forfeit coming to clinic in order to limit exposure to	
289	CO	VID-19, and those living in remote locations, could utilize VVP-10 to assess their visual	
290	function, potentially providing equivalent or complementary data to in-clinic visual field testing.		
291	References:		
292 293 294	1.	Glen FC, Baker H, Crabb DP. A qualitative investigation into patients' views on visual field testing for glaucoma monitoring. <i>BMJ Open</i> . 2014;4(1):e003996. doi:10.1136/bmjopen-2013-003996	
295 296 297 298	2.	Montolio FGJ, Wesselink C, Gordijn M, Jansonius NM. Factors That Influence Standard Automated Perimetry Test Results in Glaucoma: Test Reliability, Technician Experience, Time of Day, and Season. <i>Invest Ophthalmol Vis Sci.</i> 2012;53(11):7010-7017. doi:10.1167/iovs.12-10268	
299 300	3.	Kutzko KE, Brito CF, Wall M. Effect of instructions on conventional automated perimetry. <i>Invest Ophthalmol Vis Sci.</i> 2000;41(7):2006-2013.	
301 302 303	4.	Gardiner SK, Demirel S. Assessment of Patient Opinions of Different Clinical Tests Used in the Management of Glaucoma. <i>Ophthalmology</i> . 2008;115(12):2127-2131. doi:10.1016/j.ophtha.2008.08.013	
304 305 306	5.	Wu Z, Saunders LJ, Daga FB, Diniz-Filho A, Medeiros FA. Frequency of Testing to Detect Visual Field Progression Derived Using a Longitudinal Cohort of Glaucoma Patients. <i>Ophthalmology</i> . 2017;124(6):786-792. doi:10.1016/j.ophtha.2017.01.027	
307 308 309	6.	Stein JD, Talwar N, LaVerne AM, Nan B, Lichter PR. Racial Disparities in the Use of Ancillary Testing to Evaluate Individuals With Open-Angle Glaucoma. <i>Archives of Ophthalmology</i> . 2012;130(12):1579-1588. doi:10.1001/archophthalmol.2012.1325	

310311312	Gracitelli CPB, Zangwill LM, Diniz-Filho A, et al. Detection of Glaucoma Progression in Individuals of African Descent Compared With Those of European Descent. <i>JAMA</i> <i>Ophthalmology</i> . 2018;136(4):329-335. doi:10.1001/jamaophthalmol.2017.6836
313 8.314315	Stagg B, Mariottoni EB, Berchuck S, et al. Longitudinal visual field variability and the ability to detect glaucoma progression in black and white individuals. <i>British Journal of Ophthalmology</i> . Published online May 12, 2021. doi:10.1136/bjophthalmol-2020-318104
316 9.317318	Sukumar S, Spencer F, Fenerty C, Harper R, Henson D. The influence of socioeconomic and clinical factors upon the presenting visual field status of patients with glaucoma. <i>Eye</i> . 2009;23(5):1038-1044. doi:10.1038/eye.2008.245
319 10.320321	Chauhan BC, Garway-Heath DF, Goñi FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. <i>British Journal of Ophthalmology</i> . 2008;92(4):569-573. doi:10.1136/bjo.2007.135012
322 11. 323 324	European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminologySupported by the EGS Foundation. <i>Br J</i> <i>Ophthalmol</i> . 2017;101(5):73-127. doi:10.1136/bjophthalmol-2016-EGSguideline.002
325 12. 326 327 328	Fung SSM, Lemer C, Russell RA, Malik R, Crabb DP. Are practical recommendations practiced? A national multi-centre cross-sectional study on frequency of visual field testing in glaucoma. <i>British Journal of Ophthalmology</i> . 2013;97(7):843-847. doi:10.1136/bjophthalmol-2012-302903
329 13. 330	Gedde SJ, Vinod K, Wright MM, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. <i>Ophthalmology</i> . 2021;128(1):P71-P150. doi:10.1016/j.ophtha.2020.10.022
 331 14. 332 333 	Stagg BC, Stein JD, Medeiros FA, et al. The Frequency of Visual Field Testing in a US Nationwide Cohort of Individuals with Open-Angle Glaucoma. <i>Ophthalmology Glaucoma</i> . Published online May 20, 2022. doi:10.1016/j.ogla.2022.05.002
334 15.335336	Jones L, Callaghan T, Campbell P, et al. Acceptability of a home-based visual field test (Eyecatcher) for glaucoma home monitoring: a qualitative study of patients' views and experiences. <i>BMJ Open.</i> 2021;11(4):e043130. doi:10.1136/bmjopen-2020-043130
337 16.338339340	Hu GY, Prasad J, Chen DK, Alcantara-Castillo JC, Patel VN, Al-Aswad LA. Home Monitoring of Glaucoma Using a Home Tonometer and a Novel Virtual Reality Visual Field Device: Acceptability and Feasibility. <i>Ophthalmol Glaucoma</i> . Published online May 14, 2022:S2589-4196(22)00081-3. doi:10.1016/j.ogla.2022.05.001
341 17.342343	Greenfield JA, Deiner M, Nguyen A, et al. Virtual Reality Oculokinetic Perimetry Test Reproducibility and Relationship to Conventional Perimetry and OCT. <i>Ophthalmology</i> <i>Science</i> . 2022;2(1). doi:10.1016/j.xops.2021.100105
344 18. 345 346	Deiner MS, Damato BE, Ou Y. Implementing and Monitoring At-Home Virtual Reality Oculo-kinetic Perimetry During COVID-19. <i>Ophthalmology</i> . 2020;127(9):1258. doi:10.1016/j.ophtha.2020.06.017

347 348 349 350	19.	McTrusty AD, Cameron LA, Perperidis A, et al. Comparison of Threshold Saccadic Vector Optokinetic Perimetry (SVOP) and Standard Automated Perimetry (SAP) in Glaucoma. Part II: Patterns of Visual Field Loss and Acceptability. <i>Transl Vis Sci Technol</i> . 2017;6(5). doi:10.1167/tvst.6.5.4
351 352	20.	Wall M, Kutzko KE, Chauhan BC. Variability in patients with glaucomatous visual field damage is reduced using size V stimuli. <i>Invest Ophthalmol Vis Sci.</i> 1997;38(2):426-435.
353 354 355 356	21.	Wall M, Woodward KR, Doyle CK, Artes PH. Repeatability of Automated Perimetry: A Comparison between Standard Automated Perimetry with Stimulus Size III and V, Matrix, and Motion Perimetry. <i>Investigative Ophthalmology & Visual Science</i> . 2009;50(2):974-979. doi:10.1167/iovs.08-1789
357 358 359	22.	Dul MW, Backus B, Haimowitz C, Blaha J. Effects of Optical Defocus on Decrement Perimetric Stimuli with Pattern Blur. <i>Investigative Ophthalmology & Visual Science</i> . 2019;60(9):2490.
360 361 362	23.	Yu HJ, Kiernan DF, Eichenbaum D, Sheth VS, Wykoff CC. Home Monitoring of Age- Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. <i>Ophthalmol Retina</i> . 2021;5(4):348-356. doi:10.1016/j.oret.2020.08.003
363 364 365 366	24.	Chew EY, Clemons TE, Bressler SB, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1. <i>Contemp Clin Trials</i> . 2014;37(2):294-300. doi:10.1016/j.cct.2014.02.003
367 368 369	25.	Chauhan BC, Johnson CA. Test-retest variability of frequency-doubling perimetry and conventional perimetry in glaucoma patients and normal subjects. <i>Invest Ophthalmol Vis Sci.</i> 1999;40(3):648-656.
370 371 372 373	26.	Jones PR, Campbell P, Callaghan T, et al. Glaucoma Home Monitoring Using a Tablet- Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months. <i>American Journal of Ophthalmology</i> . 2021;223:42-52. doi:10.1016/j.ajo.2020.08.039
374 375 376	27.	Prea SM, Vingrys AJ, Kong GYX. Test Reliability and Compliance to a Twelve-Month Visual Field Telemedicine Study in Glaucoma Patients. <i>J Clin Med.</i> 2022;11(15):4317. doi:10.3390/jcm11154317
377 378 379	28.	Razeghinejad R, Gonzalez-Garcia A, Myers JS, Katz LJ. Preliminary Report on a Novel Virtual Reality Perimeter Compared With Standard Automated Perimetry. <i>Journal of Glaucoma</i> . 2021;30(1):17-23. doi:10.1097/IJG.000000000001670
380 381 382	29.	Stapelfeldt J, Kucur ŞS, Huber N, Höhn R, Sznitman R. Virtual Reality–Based and Conventional Visual Field Examination Comparison in Healthy and Glaucoma Patients. <i>Translational Vision Science & Technology</i> . 2021;10(12):10. doi:10.1167/tvst.10.12.10

- 383 30. Mees L, Upadhyaya S, Kumar P, et al. Validation of a Head-mounted Virtual Reality
 384 Visual Field Screening Device. *Journal of Glaucoma*. 2020;29(2):86-91.
 385 doi:10.1097/IJG.00000000001415
- 386 31. Ahmed Y, Pereira A, Bowden S, et al. Multicenter Comparison of the Toronto Portable
 387 Perimeter with the Humphrey Field Analyzer: A Pilot Study. *Ophthalmol Glaucoma*.
 388 2022;5(2):146-159. doi:10.1016/j.ogla.2021.07.011
- 32. Jones PR, Lindfield D, Crabb DP. Using an open-source tablet perimeter (Eyecatcher) as a
 rapid triage measure for glaucoma clinic waiting areas. *British Journal of Ophthalmology*.
 2021;105(5):681-686. doi:10.1136/bjophthalmol-2020-316018
- 33. Schulz AM, Graham EC, You Y, Klistorner A, Graham SL. Performance of iPad-based
 threshold perimetry in glaucoma and controls. *Clinical & Experimental Ophthalmology*.
 2018;46(4):346-355. doi:10.1111/ceo.13082
- 34. Prea SM, Kong GYX, Guymer RH, Vingrys AJ. Uptake, Persistence, and Performance of
 Weekly Home Monitoring of Visual Field in a Large Cohort of Patients With Glaucoma.
 American Journal of Ophthalmology. 2021;223:286-295. doi:10.1016/j.ajo.2020.10.023
- 398 35. Muthusamy V, Turpin A, Nguyen BN, Denniss J, McKendrick AM. Patients' views of
 visual field testing and priorities for research development and translation into practice. *Ophthalmology Glaucoma*. Published online October 14, 2021.
 doi:10.1016/j.ogla.2021.10.003
- 402

19

404 Figure Legends

405

406 Figure 1: Schematic describing the steps of the test. Subjects control a pointer with their head-

- 407 movement and must connect this pointer to a fixation point (fixation task). Upon connection of
- 408 the head-pointer with the fixation point, a stimulus will flash in the periphery (stimulus task) and
- 409 subjects must move the head-pointer in the direction of the stimulus. This cycle repeats until all
- 410 points of a 24-2 grid have been tested.
- 411 Figure 2: VVP-10 and HVF grayscale maps for one subject. A) Example of ten VVP-10 session
- 412 results (top two rows, right eye; bottom two rows, left eye). Each location is represented by one
- 413 of 5 gray levels, depending how many stimuli were seen from 0 (black) to 4 (white). B) VVP-10
- 414 grayscale map with 41 gray levels after averaging results from ten individual sessions (left
- 415 column). The corresponding HVF grayscale maps for these eyes is shown in the right column.
- 416 Data are from OD (top) and OS (bottom).
- 417 Figure 3: Relationship between the correlation of HVF point sensitivity (dB) versus VVP
- 418 fraction seen and HVF mean deviation (dB). Each data point represents an eye.
- 419 Figure 4: Correlation between VVP-10 average fraction seen versus HVF MS (dB) including A)
- 420 only eyes with MD -6 dB or worse (16 eyes total) and B) all 35 eyes included in the correlation

421 analysis.

STEP 1: Fixation task (varied locations)

"Connect the orange dots by moving your head."

STEP 2: Stimulus

At completion of STEP 1, (i.e. when dark orange head-pointer reaches light orange fixation point), a black stimulus spot briefly flashes on.

STEP 3: Response task

"Move the orange dot toward the location of where you saw a black spot, if you saw one."



OS ·





10

A)

























A)



